Retavase (reteplase)
Company: Boehringer Mannheim Corporation
Approval Status: Approved November 1996
Treatment for: patients suffering from heart attack
Areas: Cardiology/Vascular Diseases
| General Information | Clinical Results | Additional Information |
General Information
Retavase (reteplase), a new thrombolytic agent to help treat the 1.5 million American subjects suffering from heart attack each year, has been approved. Retavase is the only thrombloytic that can be given in a simple two-shot form rather than a continuous intravenous infusion.
Clinical Results
An international study of more than 6,000 subjects treated with either Retavase or streptokinase proved Retavase to be safe and effective in reducing mortality and lowering the incidence of CHF and other cardiovascular conditions. Additionally, clinical data show that Retavase was associated with a reduced need to perform emergency angioplasty compared to Alteplase.
Additional Information
Thrombolytic agents are used to treat patents that suffer from heart attack, or what is medically known as acute myocardial infarction (AMI). Widespread research has shown that one of the most effective treatments for a heart attack as a result of blockage caused by a blood clot is to quickly administer a thrombolytic agent to restore blood flow to the affected artery.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
